LRRC3B

Across TCGA pan-cancer cohorts, LRRC3B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LRRC3B data layer compared with 20 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher LRRC3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC3B expression acts as an unfavorable survival marker.

ESCA, LUAD, and PRAD are the cancer types where LRRC3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	18	view →
LUAD	OS	Median	II,III,IV	0.079	0.683	<.001	16	view →
PRAD	DFS	Median	All	0.486	0.936	<.001	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
LUSC	DFS	Median	All	0.136	0.791	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LRRC3B–ESCA (OS)

Open the ESCA breakdown →